keyword
MENU ▼
Read by QxMD icon Read
search

Mirabegron

keyword
https://www.readbyqxmd.com/read/27914999/dual-therapy-for-refractory-overactive-bladder-in-children-a-prospective-open-label-study
#1
Fannie Morin, Anne-Sophie Blais, Geneviève Nadeau, Katherine Moore, Lucie Genois, Stéphane Bolduc
PURPOSE: Mirabegron (β3-adrenoreceptor agonist) is a new molecule with a distinct mechanism of action from antimuscarinics. Combination therapy with solifenacin was recently studied in adult population. Our objective was to evaluate the efficacy and safety of mirabegron as add-on therapy, to treat urinary incontinence in children with idiopathic OAB, refractory/intolerant to antimuscarinics. MATERIALS AND METHODS: A prospective off-label study using add-on regimens of mirabegron was conducted with pediatric patients presenting no symptom improvement under intensive behavioural and medical therapies and/or significant side effects (S/E) on antimuscarinic dose escalation...
November 30, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27911988/long-term-persistence-with-mirabegron-versus-solifenacin-in-women-with-overactive-bladder-prospective-randomized-trial
#2
Manami Kinjo, Yuki Sekiguchi, Yasukuni Yoshimura, Kikuo Nutahara
OBJECTIVES: To compare persistence with medication and the reasons for discontinuation of mirabegron or solifenacin therapy up to12 months in women with overactive bladder (OAB). METHODS: Female OAB patients who presented to women's urology clinics were enrolled in a prospective, randomized, two-arm study. Patients were randomized to receive mirabegron at 25-50 mg (n = 76) or solifenacin at 2.5-5 mg (n = 72). The persistence rate and the reasons for discontinuation were investigated up to 12 months...
December 2, 2016: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/27860325/safety-and-effectiveness-of-mirabegron-in-patients-with-overactive-bladder-in-a-real-world-clinical-setting-a-japanese-post-marketing-study
#3
Yumiko Nozawa, Daisuke Kato, Hiromi Tabuchi, Kentarou Kuroishi
OBJECTIVES: To provide real-world data on Japanese patients with overactive bladder (OAB) initiating treatment with the β3 -adrenoceptor agonist, mirabegron. This study examined prescribing patterns, adverse drug reaction (ADR) incidence, and treatment effectiveness. METHODS: Full medical histories, including prior/concomitant drug use, were collected before initiating mirabegron treatment. After 12 weeks mirabegron, physicians assessed ADR incidence and treatment effectiveness...
November 17, 2016: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/27845121/re-the-efficacy-of-mirabegron-additional-therapy-for-lower-urinary-tract-symptoms-after-treatment-with-%C3%AE-1-adrenergic-receptor-blocker-monotherapy-prospective-analysis-of-elderly-men
#4
https://www.readbyqxmd.com/read/27829538/pharmacokinetic-drug-interaction-study-between-overactive-bladder-drugs-mirabegron-and-tolterodine-in-japanese-healthy-postmenopausal-females
#5
Yuki Nomura, Hiromi Iitsuka, Junko Toyoshima, Kentaro Kuroishi, Toshifumi Hatta, Atsunori Kaibara, Masataka Katashima, Selina Moy, Taiji Sawamoto
Mirabegron, the first selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6. This study was performed in Japanese healthy postmenopausal female volunteers to assess any pharmacokinetic drug interaction between mirabegron and tolterodine, another OAB drug and a sensitive substrate of CYP2D6. Tolterodine 4 mg was orally administered from Days 1-7 and co-administered with mirabegron 50 mg from Days 8-14. Mirabegron 50 mg increased maximum concentration (Cmax) and area under the concentration-time curve from zero to 24 h after dosing (AUC24h) of tolterodine by 2...
August 18, 2016: Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/27828840/high-satisfaction-with-direct-switching-from-antimuscarinics-to-mirabegron-in-patients-receiving-stable-antimuscarinic-treatment
#6
Chun-Hou Liao, Hann-Chorng Kuo
Mirabegron, which was the first β3-adrenoceptor agonist introduced for use in clinical practice, has been extensively evaluated in overactive bladder (OAB) patients in several phase II and III studies. However, most of the enrolled patients were treatment naive or had experienced a wash-out period before the introduction of mirabegron. No study has reported the treatment results of a direct switch from antimuscarinics to mirabegron, which may more commonly occur in clinical practice. This is an observational study to assess the therapeutic efficacy and safety of directly switching from antimuscarinics to mirabegron in patients with OAB receiving stable antimuscarinic treatment...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27794199/long-term-treatment-with-the-beta-3-adrenoceptor-agonist-mirabegron-ameliorates-detrusor-overactivity-and-restores-cyclic-adenosine-monophosphate-camp-levels-in-obese-mice
#7
Fabiano B Calmasini, Mariana G de Oliveira, Eduardo C Alexandre, Fábio H da Silva, Carmem P V da Silva, Tuany Z Candido, Edson Antunes, Fabíola Z Mónica
AIMS: To evaluate the effects of the beta-3 adrenoceptor agonist, mirabegron in a mouse model of detrusor overactivity induced by obesity. METHODS: C57BL/6 male mice were fed with standard chow or high-fat diet for 12 weeks. Lean and obese mice were treated orally with mirabegron (10 mg/kg/day) from the last 2 weeks of diet. Cystometric evaluations, functional assays, protein expression for phosphodiesterase type 4 (PDE4), and cyclic adenosine monophosphate (cAMP) measurement were carried out...
October 29, 2016: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/27765725/oral-sustained-release-suspension-based-on-a-lauryl-sulfate-salt-complex
#8
Yuuki Kasashima, Shinya Uchida, Keiichi Yoshihara, Takehiko Yasuji, Kazuhiro Sako, Noriyuki Namiki
The objective of this study was to evaluate the feasibility of lauryl sulfate (LS) salt/complex as a novel carrier in oral sustained-release suspensions. Mirabegron, which has a pH-dependent solubility, was selected as the model drug. Sodium lauryl sulfate (SLS) was bound to mirabegron in a stoichiometric manner to form an LS salt/complex. LS salt/complex formulation significantly reduced the solubility of mirabegron and helped mirabegron achieve sustained-release over a wide range of pH conditions. Microparticles containing the LS salt/complex were prepared by spray drying with the aqueous dispersion of ethylcellulose (Aquacoat(®) ECD)...
October 17, 2016: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/27738922/a-short-review-of-drug-food-interactions-of-medicines-treating-overactive-bladder-syndrome
#9
Paweł Paśko, Tomasz Rodacki, Renata Domagała-Rodacka, Danuta Owczarek
Background Overactive bladder syndrome is a condition where one or more of the symptoms such as pollakiuria, urgent need to urinate, nocturia and urinary incontinence is observed. Its prevalence ranges between 7 and 27 % in men and 9-43 % in women. The role of a pharmacist is to educate the patient on medications administration scheme, and drug interactions with particular food or food components. Aim of the review To assess a potential impact of food and fruit juice on the pharmacokinetic and therapeutic effects of medications used in treating overactive bladder syndrome...
December 2016: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/27695622/mirabegron-in-overactive-bladder-patients-efficacy-review-and-update-on-drug-safety
#10
Katherine Warren, Helena Burden, Paul Abrams
Overactive bladder is a common condition, which significantly affects people's quality of life. The use of anticholinergic medication has been the mainstay of managing overactive bladder when conservative measures are not enough. Many patients stop anticholinergic medication because of the side effects and more recently the concerns about the effect of an anticholinergic burden and the development of dementia have been studied. Activation of β3 adrenoceptors has been shown to relax the detrusor muscle and subsequently lead to the development of the first β3 adrenoceptor agonist...
October 2016: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/27686226/comparison-of-mirabegron-and-imidafenacin-for-efficacy-and-safety-in-japanese-female-patients-with-overactive-bladder-a-randomized-controlled-trial-comfort-study
#11
Atsushi Otsuka, Shinji Kageyama, Takahisa Suzuki, Rikiya Matsumoto, Hiroshi Nagae, Motoaki Kitagawa, Hiroshi Furuse, Seiichiro Ozono
OBJECTIVES: To evaluate the efficacy and safety of mirabegron compared with imidafenacin for the treatment of female patients with overactive bladder. METHODS: Patients (n = 89) were randomized to receive 0.1 mg imidafenacin twice daily (n = 47) or 50 mg mirabegron once daily (n = 42) for 12 weeks. The primary efficacy end-point was change in total Overactive Bladder Symptom Score. Secondary efficacy end-points included change in Overactive Bladder Symptom Score, 3-day micturition diary, International Prostate Symptom Score and Overactive Bladder Questionnaire...
December 2016: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/27624693/real-world-cardiovascular-assessment-of-mirabegron-treatment-in-patients-with-overactive-bladder-and-concomitant-cardiovascular-disease-results-of-a-japanese-post-marketing-study
#12
Takao Katoh, Kana Kuwamoto, Daisuke Kato, Kentarou Kuroishi
OBJECTIVES: To assess the effect of 25 or 50 mg mirabegron on cardiovascular end-points and adverse drug reactions in real-world Japanese patients with overactive bladder and cardiovascular disease. METHODS: Participants had overactive bladder, a history of/coexisting cardiovascular disease and a 12-lead electrocardiogram carried out ≤7 days before initiating 4 weeks of mirabegron treatment. Patients with "serious cardiovascular disease" (class III or IV on the New York Heart Association functional classification and further confirmed by expert analysis) were excluded...
December 2016: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/27619782/urodynamic-efficacy-and-safety-of-mirabegron-add-on-treatment-with-tamsulosin-for-japanese-male-patients-with-overactive-bladder
#13
Naoki Wada, Hiromichi Iuchi, Masafumi Kita, Kazumi Hashizume, Seiji Matsumoto, Hidehiro Kakizaki
OBJECTIVES: To investigate urodynamic efficacy and safety of mirabegron add-on treatment with tamsulosin for Japanese male patients with overactive bladder (OAB). METHODS: A prospective study was conducted in 26 consecutive male patients with OAB who had been taking tamsulosin. OAB was diagnosed by overactive bladder symptom score (OABSS). Before and 8 weeks after mirabegron add-on treatment with preceding tamsulosin, we assessed OABSS, International Prostate Symptom Score (IPSS), free uroflowmetry (UFM), filling cystometry and pressure-flow study (PFS)...
September 2016: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/27600952/beta3-adrenoreceptor-agonist-mirabegron-a-potential-antiobesity-drug
#14
Vojtech Hainer
No abstract text is available yet for this article.
September 6, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27581634/oral-sustained-release-of-a-hydrophilic-drug-using-the-lauryl-sulfate-salt-complex
#15
Yuuki Kasashima, Keiichi Yoshihara, Takehiko Yasuji, Kazuhiro Sako, Shinya Uchida, Noriyuki Namiki
The objective of this study was to establish the key factor of the lauryl sulfate (LS) salt/complex for sustained release of a hydrophilic drug at various physiological pH levels. Mirabegron is a hydrophilic drug that exhibits pH-dependent solubility. Sodium lauryl sulfate (SLS) bound to mirabegron in a stoichiometric manner. The formation of the LS salt/complex significantly reduced mirabegron solubility and helped achieve sustained release of mirabegron over a wide range of pH levels. In addition to SLS, other additives containing a sulfate group formed salts/complexes with mirabegron and reduced its solubility at different pH levels...
2016: Chemical & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/27579830/estimated-budget-impact-of-increased-use-of-mirabegron-a-novel-treatment-for-overactive-bladder
#16
Sinem Perk, Ronald C Wielage, Noll L Campbell, Timothy M Klein, Anthony Perkins, Linda M Posta, Thomas Yuran, Robert W Klein, Daniel B Ng
BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB population untreated. Antimuscarinics also contribute to a patient's anticholinergic cognitive burden (ACB), so the Beers Criteria recommends cautious use of antimuscarinics in elderly patients who take multiple anticholinergic medications or have cognitive impairment...
September 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27574750/estimated-budget-impact-of-increased-use-of-mirabegron-a-novel-treatment-for-overactive-bladder
#17
Sinem Perk, Ronald C Wielage, Noll L Campbell, Timothy M Klein, Anthony Perkins, Linda M Posta, Thomas Yuran, Robert W Klein, Daniel B Ng
BACKGROUND: Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron. Antimuscarinic adverse events (AEs) such as dry mouth, constipation, and blurry vision can result in frequent treatment discontinuation rates, leaving part of the OAB population untreated. Antimuscarinics also contribute to a patient's anticholinergic cognitive burden (ACB), so the Beers Criteria recommends cautious use of antimuscarinics in elderly patients who take multiple anticholinergic medications or have cognitive impairment...
September 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27567206/re-efficacy-and-safety-of-mirabegron-add-on-therapy-to-solifenacin-in-incontinent-overactive-bladder-patients-with-an-inadequate-response-to-initial-4-week-solifenacin-monotherapy-a-randomised-double-blind-multicentre-phase-3b-study-beside
#18
https://www.readbyqxmd.com/read/27529461/hormonal-influence-on-the-effect-of-mirabegron-treatment-for-overactive-bladder
#19
Helena Kopp Kallner, Caroline Elmér, Karl-Erik Andersson, Daniel Altman
OBJECTIVE: The aim of this study was to evaluate if levels of gonadotropic and sex steroidal hormones influence the efficacy of mirabegron in the treatment of overactive bladder. METHODS: We included 58 female participants who received treatment with mirabegron 50 mg once daily and provided a blood sample for hormone profiling before treatment was initiated. Serum hormone concentrations for estradiol, progesterone, testosterone, FSH, LH, TSH, and T4 were analyzed...
December 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27514371/combination-treatment-with-mirabegron-and-solifenacin-in-patients-with-overactive-bladder-exploratory-responder-analyses-of-efficacy-and-evaluation-of-patient-reported-outcomes-from-a-randomized-double-blind-factorial-dose-ranging-phase-ii-study-symphony
#20
P Abrams, C Kelleher, D Staskin, R Kay, A Martan, I Mincik, D Newgreen, A Ridder, A Paireddy, R van Maanen
PURPOSE: This large dose-ranging study explored the benefits of different combinations of mirabegron and solifenacin on health-related quality of life (HRQoL), based on patient-reported outcomes (PROs), and patients ('responders') achieving clinically meaningful improvements in efficacy and HRQoL. METHODS: SYMPHONY (NCT01340027) was a Phase II, placebo- and monotherapy-controlled, dose-ranging, 12-week trial. Adult patients with overactive bladder (OAB) for ≥3 months were randomized to 1 of 12 groups: 6 combination (solifenacin 2...
August 11, 2016: World Journal of Urology
keyword
keyword
7718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"